Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week. The E&C Committee has jurisdiction over the 340B program.
The June 29 hearing was on 11 healthcare bills, none related to the 340B program. Dingell asked a witness—Desiree Sweeney, CEO of NEW Health, a health center in rural northeast Washington state—about the 340B program’s impact on underserved communities.
Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
